Related Experiment Video
Updated: Jun 12, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy
V V S Naresh1, A L K Reddy, G Sivaramakrishna
1Department of Nephrology, Sri Venkateswara Institute of Medical Sciences, Sri Venkateswara University, Tirupati - 517 507, India.
Indian Journal of Nephrology
|June 11, 2010
Summary
Genetic factors influence diabetic nephropathy. This study found a link between the angiotensin converting enzyme (ACE) DD gene polymorphism and type II diabetes with nephropathy.
Area of Science:
- Nephrology
- Genetics
- Endocrinology
Background:
- Diabetic nephropathy is a common complication of type II diabetes.
- Genetic predisposition is a significant factor in developing diabetic nephropathy.
- The angiotensin converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism is implicated in nephropathy.
Purpose of the Study:
- To investigate the association between ACE I/D gene polymorphism and type II diabetes with or without nephropathy.
Main Methods:
- Genotyping of ACE I/D polymorphism in 60 patients.
- Patients were divided into two groups: type II diabetes without nephropathy (30 patients) and type II diabetes with nephropathy (30 patients).
Main Results:
- The study suggests an association between the ACE DD genotype and type II diabetes with nephropathy.
- The deletion polymorphism (DD) of the ACE gene may be linked to increased enzyme activity, potentially contributing to nephropathy.
Conclusions:
- The DD polymorphism of the ACE gene is associated with an increased risk of developing nephropathy in patients with type II diabetes.
- Further research is warranted to elucidate the precise mechanisms linking ACE I/D polymorphism to diabetic nephropathy.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...